# To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

> **NCT05400876** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 92 (estimated)

## Conditions studied

- Relapsed/Refractory Lymphoma

## Interventions

- **DRUG:** TQB2618 injection
- **DRUG:** Penpulimab injection

## Key facts

- **NCT ID:** NCT05400876
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-09
- **Primary completion:** 2023-05
- **Final completion:** 2023-10
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05400876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05400876, "To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05400876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*